Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Eli Lilly's stock drops as it slashes the price of Zepbound: Time to buy the dip?

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...
WHIO

Eli Lilly, Walmart partner to bring Zepbound to customers with direct-to-consumer pricing

Eli Lilly and Company and Walmart have announced a partnership to offer Zepbound single-dose vials at Walmart pharmacies. The move will start nationwide in mid-November and will have direct-to ...

A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Think Eli Lilly Is Expensive? This Metric Says Otherwise.

Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook ...

Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...